Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: a prospective randomised clinical trial

Ann Med. 2021 Dec;53(1):1589-1597. doi: 10.1080/07853890.2021.1974083.

Abstract

Introduction: In puerperium, the hypoestrogenic state induced by delivery and subsequently sustained by lactation may lead to vaginal dryness, burning, and itching sensation, contributing to the onset of sexual dysfunction.

Material and methods: This was a prospective, randomized, controlled, open-label study (NCT04560283) for evaluating the effects of application of a prolonged-release hyaluronic acid derivative vaginal gel in restoring sexual function during the postpartum period. Eighty-five patients were randomized to apply prolonged-release Hydeal-D 0.2% vaginal gel (Fidia Farmaceutici, Abano Terme, Italy; n = 43) every three days for 12 consecutive weeks or expectant management (n = 42).

Results: Women undergoing treatment had a more elevate increase in Female Sexual Function Index (FSFI) total score (+15.1 ± 11.9 vs +6.5 ± 8.9, p < 0.001) and a higher decrease in vaginal pH (-1.2 ± 0.7 vs -0.2 ± 1.1; p < 0.001). Moreover, the proportion of vaginal smears with maturation index (VMI) >65 was significantly higher in patients treated (80.6% vs 35.3%; p = 0.004). Edinburgh Postnatal Depression Scale (EPDS) decreased significantly in both groups with no inter-group difference (p = 0.459). Only two cases (4.8%) of moderate vaginal burning sensation were reported in patients undergoing local vaginal therapy.

Conclusions: The results of our study demonstrated that hyaluronic acid derivative vaginal gel (Hydeal-D) was able to improve sexual function of puerperal women in the short-term treatment.KEY MESSAGEIn the puerperium, the hypoestrogenic state induced by delivery and subsequently sustained by lactation may lead to vaginal dryness, burning, and itching sensation, contributing to the onset of sexual dysfunction.Hydeal-D is a prolonged-release hyaluronic acid derivative characterised by elevated resistance to enzymatic breakdown. During puerperium, its local application may improve the vaginal microenvironment by ensuring a better migration and proliferation of cells involved in local tissue repair.Among puerperal women, Hydeal-D vaginal gel causes a significant improvement of sexual function, including desire, arousal, and lubrification, compared to expectant management. Furthermore, it leads to a decrease in vaginal pH and an increase of the trophic status of vaginal epithelium.

Keywords: Prolonged-release hyaluronic acid derivative vaginal gel; hydeal-D; postnatal depression; randomised trial; sexual function; vaginal dryness; vaginal lubrification; vaginal maturation index; vaginal pH.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Depression, Postpartum
  • Female
  • Humans
  • Hyaluronic Acid / administration & dosage*
  • Hyaluronic Acid / therapeutic use
  • Italy / epidemiology
  • Postpartum Period*
  • Prospective Studies
  • Pruritus
  • Sexual Dysfunction, Physiological / drug therapy*
  • Sexual Dysfunction, Physiological / epidemiology
  • Sexual Dysfunction, Physiological / psychology
  • Vaginal Creams, Foams, and Jellies / administration & dosage*
  • Vaginal Creams, Foams, and Jellies / therapeutic use
  • Vaginal Diseases / drug therapy*
  • Vaginal Diseases / epidemiology

Substances

  • Vaginal Creams, Foams, and Jellies
  • Hyaluronic Acid

Associated data

  • ClinicalTrials.gov/NCT04560283

Grants and funding

Fidia Farmaceutici (Abano Terme, Italy) covered the cost of Hydead-D for the patients involved in the study and sustained the cost of statistical analysis.